A 32-year-old man on peritoneal dialysis (PD) was hospitalized for seven days due to fever. A diagnosis of yeast-like fungal peritonitis was made by Gram staining. The patient was started on intravenous micafungin and oral fluconazole therapy following removal of the PD catheter. A fungal pathogen was isolated from the peritoneal fluid and identified as Cryptococcus species. Based on antifungal susceptibility testing, the treatment was changed to voriconazole and continued for 3 months. A genetic analysis identified the isolate as Cryptococcus laurentii (C. laurentii). This patient was diagnosed with C. laurentii PD-related peritonitis and was successfully treated with voriconazole and removal of the PD catheter.
Introduction
Peritonitis is a major and potentially serious complication of peritoneal dialysis (PD) therapy and is one of the important reasons for withdrawal from PD (1) . Although the most commonly identified pathogens are bacteria, fungal peritonitis is very serious and catheter removal is strongly recommended immediately following fungal identification by microscopy or culture (2) . Candida species are reportedly the most frequently isolated fungi in PD-related peritonitis patients (3) . Cryptococcal peritonitis is unusual and, to our knowledge, only 12 cases have been reported previously (4) (5) (6) (7) .
Cryptococcus neoformans infection in immunocompromised hosts is the most common of the cryptococcal infections. Other Cryptococcus species have traditionally been considered to be non-pathogenic (8) . However, the incidence of infection due to these organisms, such as Cryptococcus laurentii (C. laurentii) and Cryptococcus albidus (C. albidus), has increased over the past four decades (8, 9) . We know of two reported cases of peritonitis in PD patients caused by C. laurentii (10, 11) . We herein report a case of peritonitis caused by C. laurentii in an adult patient on PD. To our knowledge, this is the first reported case of C. laurentii PD-related peritonitis that was successfully treated by voriconazole and the removal of the catheter.
Case Report
A 32-year-old man with IgA nephropathy had been on continuous ambulatory peritoneal dialysis (CAPD) since age 29. At age 30, CAPD was changed to combination PD and hemodialysis (HD) therapy. The PD bag exchange protocol was as follows: 2.5% glucose-based solution (Dianeal-N PD-2 2.5% TM ; Baxter, Tokyo, Japan) 2 L×3/daytime and icodextrin solution (Extraneal TM ; Baxter, Tokyo, Japan) 2 L/ overnight. To change PD fluid (PDF) bags, the patient used a sterile connecting UV flash device (Clean Flash ; Baxter). He was not treated with any immunosuppressive therapies, Department of Nephrology, Handa Municipal Hospital, Japan, Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Japan, Department of Bacteriology, Osaka City University Graduate School of Medicine, Japan and Department of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Japan The Testing was Performed according to the CLSI-M27-A3 Guidelines and a serological test for human immunodeficiency virus (HIV) was negative. The patient had never previously experienced peritonitis before this episode and had not taken any antibiotics for more than six months. He presented to our hospital complaining of fever for the past seven days. His vital signs were as follows: blood pressure, 137/82 mmHg; pulse, 78/min; respiratory rate, 16/min; and temperature, 37.3 . On physical examination, no abdominal tenderness was found. The clinical laboratory data at admission were as follows: peripheral white blood cell (WBC) count, 4,400 cells/mm 3 (neutrophils, 69%; lymphocytes, 12.7%; eosinophils, 8.8%); blood hemoglobin level, 14.2 g/dL; and C-reactive protein level, 4.0 mg/dL. The serum cryptococcal antigen test (Eiken-Latex agglutination test; Sero direct , Tokyo, Japan) was negative. A Tenckhoff catheter was in place in the left lower quadrant and did not appear to be infected. When PDF exchange was performed at the hospital, the peritoneal fluid was noted to be cloudy. The WBC count in the first cloudy PDF was 3,500 cells/ mm 3 (neutrophils, 60%; lymphocytes, 26%; eosinophils, 14%), indicating peritonitis. Gram staining of the centrifuged PDF sediment was performed, and yeast cells with large Gram-positive budding structures were identified by microscopy (Fig. 1A ). Blood and sputum cultures collected at admission were negative. These findings suggested fungal peritonitis, and administration of intravenous micafungin and oral fluconazole was initiated. Although the number of WBCs in the effluent tended to decrease with antifungal treatment, the WBC counts remained steady at 1,000/mm 3 . The peritoneal catheter was removed on admission day 7 according to the recommendation of the International Society for Peritoneal Dialysis (ISPD) guidelines, although there was no sign of infection around the cuffs and cultures of the tip of the catheter were negative. A fungal pathogen grew from the initial PDF, and the isolate was identified as a Cryptococcus species by a commercial laboratory 10 days after admission. In addition, India ink staining of the isolate showed capsule formation around the cells, consistent with the identification of a Cryptococcal species (Fig. 1B) . Based on the antifungal susceptibility testing results (Table) , the treatment was altered to the oral administration of voriconazole at a dose of 400 mg/day. The trough level of voriconazole was 0.35 μg/mL, which is lower than the recommended dose in the guidelines (12); therefore, we increased the dose of voriconazole to 600 mg/day. The patient's CRP levels improved and he was discharged on admission day 18. He has been in good condition for more than one year after completing 3 months of antibiotic therapy. Further identification of the isolate was subsequently performed by the National Institute of Infectious Diseases (Tokyo, Japan), and the isolate was identified as C. laurentii by sequencing the internal transcribed spacer (ITS) and D1/D2 regions of the ribosomal RNA, as previously described (13) . The clinical course is summarized in Fig. 2 .
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Discussion
Fungal peritonitis in PD patients is a serious complication, leading to death in approximately 25% of episodes (14, 15) . Although the majority of cryptococcal infections are due to C. neoformans (16) , the incidence of infection due to other Cryptococcus species, such as C. laurentii and C. albidus, has increased over the past four decades (8, 9) . There have been reports of lung, eye and cutaneous infections, meningitis, and fungemia caused by C. laurentii and C. albidus (8, 9) . A review of the cryptococcal PD-related peritonitis literature was performed by Yinnon et al. (4, 5) . This report included 10 cases of cryptococcal peritonitis during CAPD, and 2 of these 10 patients died. Cultures of samples yielded C. laurentii in 2 cases, and C. neoformans in 6 cases, but the Cryptococcus species of the remaining 2 cases were not stated. Therefore, to the best of our knowledge, only 2 cases of peritonitis in PD patients caused by C. laurentii have been reported (10, 11) . The PD catheters were removed in these 2 cases, resulting in successful treatment and survival (10, 11) . Both were adolescent females, and neither was on immunosuppressive therapy. The natural habitats of C. laurentii are unknown (8, 9) , and therefore we could not precisely identify the infection route for the current patient. However, these previous reports and our present case suggest that an indwelling PD catheter may be a risk factor even without significant immunosuppressive therapy.
Primary resistance to fluconazole and flucytosine has been reported in Cryptococcus species other than C. neoformans (17) , although the interpretative clinical minimum inhibitory concentration (MIC) breakpoints in C. laurentii have not been determined. In the current case, the isolated C. laurentii had low MICs for itraconazole, amphotericin B and voriconazole, while the MIC for fluconazole was relatively high and the MIC for flucytosine was over the upper limit (Table) . As far as we could determine, there is no previous report of the use of voriconazole to treat cryptococcal peritonitis in general, or specifically C. laurentii infection.
In the previous reports, C. laurentii infections were successfully treated by combinations of amphotericin B, fluconazole and flucytosine, or intravenous amphotericin B alone (8) . However, the use of intravenous amphotericin B results in poor peritoneal bioavailability (18) . The intraperitoneal administration of amphotericin B causes chemical peritonitis associated with severe pain (18) . Conversely, dose adjustment was not necessary when voriconazole was administered to patients on PD therapy (19) . In addition, in vitro activities of voriconazole, posaconazole and fluconazole against 237 C. neoformans isolates were assessed by Pfaller et al. (20) who reported that voriconazole was more active than fluconazole. Furthermore, the ISPD guideline states that voriconazole is effective against fungal peritonitis, but there is no statement indicating that itraconazole is effective (2). Considered together, this information suggests that voriconazole is an effective agent for the treatment of cryptococcal peritonitis. Based on these data and information, we selected voriconazole to treat the current patient.
Experience regarding the optimal duration of treatment for C. laurentii infections is limited due to the limited number of reported cases and lack of controlled trial data. However, it was reported that a PD patient with C. neoformans peritonitis died after nine weeks of treatment with antifungal drugs, including amphotericin B; at the postmortem examination, cryptococcosis in the lung, spleen and brain was revealed (5). Our patient was successfully treated by 3 months of voriconazole. Further accumulation of data from successfully-treated cases will inform future decisions regarding selection of the most suitable antifungal agents and the optimal duration of treatment for C. laurentii PD-related peritonitis.
The authors state that they have no Conflict of Interest (COI).
